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EPIDEMIOLOGY
HIV Transmission Chains Exhibit Greater HLA-B
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Background: HIV’s capacity to escape immune recognition by
human leukocyte antigen (HLA) is a core component of HIV
pathogenesis. A better understanding of the distribution of HLA
class I in HIV-infected patients would improve our knowledge of
pathogenesis in relation to the host HLA type and could better
improve therapeutic strategies against HIV.
Materials and Methods: Three hundred one to 325 transmission
pairs and 469–496 clusters were identified for analysis among Swiss
HIV Cohort Study (SHCS) participants using HIV pol sequences
from the drug resistance database. HLA class I data were compiled at
3 specificity levels: 4-digit, 2-digit alleles, and HLA-B supertype.
The analysis tabulated HLA-I homogeneity as 2 measures: the
proportion of transmission pairs, which are HLA concordant, and the
average percentage of allele matches within all clusters. These
measures were compared with the mean value across randomizations
with randomly assorted individuals.
Results: We repeated the analysis for different HLA classification
levels and separately for HLA-A, -B, and -C. Subanalyses by the risk
group were performed for HLA-B. HLA-B showed significantly
greater homogeneity in the transmission chains (2-digit clusters: 0.291
vs. 0.251, P value = 0.009; supertype clusters: 0.659 vs. 0.611, P
value = 0.002; supertype pairs: 0.655 vs. 0.608, P value = 0.014). Risk
group restriction caused the effect to disappear for men-who-have-sex-
with-men but not for other risk groups. We also examined if protective
HLA alleles B27 and B57 were under- or overrepresented in the
transmission chains, although this yielded no significant pattern.
Conclusions: The HLA-B alleles of patients within HIV-1 transmission
chains segregate in homogenous clusters/pairs, potentially indicating
preferential transmission among HLA-B concordant individuals.
Key Words: HLA, coevolution, transmission chains
(J Acquir Immune Defic Syndr 2019;81:508–515)
Received for publication November 19, 2018; accepted March 27, 2019.
From the aDivision of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland; bInstitute of Medical
Virology, Swiss National Center for Retroviruses, University of Zurich, Zurich, Switzerland; cSchool of Life Sciences, École Polytechnique Fédérale de
Lausanne, Lausanne, Switzerland; dSwiss Institute of Bioinformatics, Lausanne, Switzerland; eLaboratory of Virology, Geneva University Hospital, University
of Geneva, Geneva, Switzerland; fDivision of Immunology and Allergy, University Hospital Lausanne, University of Lausanne, Lausanne, Switzerland;
gDepartment of Biomedicine, University of Basel, Basel, Switzerland; hDivision of Infectious Diseases and Hospital Epidemiology, Children’s Research Center,
University Children’s Hospital Zurich, Zurich, Switzerland; iUniversity Clinic of Infectious Diseases, University Hospital of Bern, University of Bern, Bern,
Switzerland; jInfectious Diseases and Infection Control Clinic, Department of Medicine, University Hospital Basel, University of Basel, Basel, Switzerland;
kDepartment of Infectious Diseases, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland; lDivision of Infectious Diseases
and Hospital Epidemiology, Kantonsspital St. Gallen, St. Gallen, Switzerland; and mDivision of Infectious Diseases, Regional Hospital, Lugano, Switzerland.
Supported by the Swiss National Science Foundation (Grant numbers BSSGI0_155851, 33CS30_177499 to H.F.G.). H.F.G. was supported by the Swiss National Science
Foundation (Grant number 179571). Furthermore, this study has been financed within the framework of the Swiss HIV Cohort Study, supported by the Swiss National
Science Foundation (Grant number 148522), by the SHCS Research Foundation, by the Yvonne Jacob Foundation (to H.F.G.), by the clinical research priority program
of the University of Zurich Viral infectious diseases, ZPHI (to H.F.G.), and the University of Zurich University Research Priority Program: Evolution in Action: From
Genomes to Ecosystems (Grant number U-702-26-01, to R.K.). H.F.G. has received an unrestricted research Grant from Gilead to the SHCS Research Foundation.
Presented at Conference on Retroviruses and Opportunistic Infections (CROI); March 4–7, 2018; Boston, MA.
H.F.G. has received unrestricted research grants from Gilead Sciences and Roche; fees for data and safety monitoring board membership from Merck; consulting/
advisory board membership fees from Gilead Sciences, Sandoz and Mepha; and travel reimbursement from Gilead. M.B. has received research or educational
grants by AbbVie AG, Gilead Sciences Switzerland Sàrl, Janssen-Cilag AG, MSD Merck Sharp & Dohme AG, and ViiV Healthcare GmbH. E.B. has
received fees for his institution for participation to advisory board from MSD, Gilead Sciences, ViiV Healthcare, AbbVie, and Janssen. M.C. has received
research and travel grants for his institution from ViiV and Gilead. T.K. has received honoraria from Gilead Sciences and Roche Diagnostics. R.D.K. has
received grants from the Swiss National Science Foundation and personal fees from Gilead Sciences, outside the submitted work. The remaining authors have
no conflicts of interest to disclose.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this
article on the journal’s Web site (www.jaids.com).
Correspondence to: Huyen Nguyen, MSc, Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zürich, Rämistrasse 100, Zürich CH-
8091 (e-mail: Huyen.nguyen@usz.ch).
Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.
508 | www.jaids.com J Acquir Immune Defic Syndr  Volume 81, Number 5, August 15, 2019
Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
s
o
u
r
c
e
:
 
h
t
t
p
s
:
/
/
d
o
i
.
o
r
g
/
1
0
.
7
8
9
2
/
b
o
r
i
s
.
1
3
1
1
2
1
 
|
 
d
o
w
n
l
o
a
d
e
d
:
 
2
7
.
1
2
.
2
0
2
0
INTRODUCTION
The pathogenesis of HIV varies vastly from individual
to individual, largely determined by the infected individual’s
immune system’s capacity to drive a clonal antigen-specific
response and the virus’ capacity for immune escape.1–3 This
mechanism hinges on the human leukocyte antigen (HLA),
a gene complex encoding for major histocompatibility
complex proteins. Major histocompatibility complex class I
proteins are found on the surface of all nucleated cells in
vertebrates and present antigens from the interior of the cell to
the exterior, allowing for binding to cytotoxic T-cells, thus
mediating the identification and destruction of virally infected
cells.4,5 The virus’ capacity to develop escape mutations to
elude HLA binding is crucial to the virus’ ability to avoid
long-term HIV control by the immune system, subsequently
facilitating the infection of other individuals.3 The high
diversity of the HLA genes is believed to be due to host-
pathogen coevolution over multiple human generations,
which drives the emergence of rarer HLA alleles that allow
for binding to a broader variety of pathogen antigens.4–6 This
coevolutionary dynamic is an important focus of recent HIV
research.7–9
HLA genes are known to affect viral progression—
some HLA alleles (eg, Cw04) are associated with a more
rapid progression to AIDS, whereas others such as B57 are
demonstrated to be protective.1,10–12 Furthermore, we
know that certain HLA-associated single-nucleotide poly-
morphisms (SNPs) are associated with HIV control. For
example, the combined variation in both the HLA and
CCR5 regions can explain 25% of the variability in viral
load.2 A statistical analysis conducted by Kaslow et al13
demonstrated that HIV-infected individuals’ HLA-I pro-
files could predict the time to the onset of AIDS. An
analysis of transmission pairs by Goepfert et al14 indicated
that HLA-B restriction by cytotoxic T lymphocytes on
escape mutations corresponded to lesser viral loads in the
recipients within transmission pairs. An individual-level
effect is observed where escape mutations specific to that
host’s HLA alleles are selected, and such mutations tend to
reverse when transmitted to another host with a different
HLA genotype.3,10,11,15,16 These dynamics may partially
explain why mother–child transmission is more likely
when there is HLA concordance.17,18 Evidence suggests
that HLA–HIV dynamics do shape the HIV epidemic—eg,
more escape mutations to protective HLA alleles are
observed over time.19 It is, however, unclear if these pro-
cesses impact the ability of the virus to be transmitted and
how they could shape epidemiological patterns.
The increasing amount of genotypic resistance sequenc-
ing data from HIV+ patients in addition to burgeoning
computational power has allowed us to construct transmission
phylogenies.20 In this study, we examined HIV transmission
chains where the individuals’ HLA type is known and
assessed the distribution of HLA alleles in transmission
chains, and if there is greater HLA homogeneity compared
with if the individuals were randomly assorted. Such insights
would improve our understanding of the coevolutionary
dynamics between HIV and HLA at the population level.
This study is the first that overlays patient HLA data over
HIV transmission data at this scale.
Better understanding the dynamics of how HIV obtains
escape mutations to avoid HLA binding and then reverts to
the wild type has implications for vaccine development as this
would help better assess the potential of T-cell–based vac-
cines.21 Insights into how the individual makeup of HLA
class I in HIV+ individuals is distributed within transmission
chains are important to understanding HIV evolutionary
dynamics, contributing to efforts in vaccine design and other
therapeutic strategies.
METHODS
Cohort
The Swiss HIV Cohort Study (SHCS) is a prospective
multicenter study with continuing enrollment of people living
with HIV in Switzerland since 1988 and covers about half of
all people ever declared to be living with HIV to the Swiss
health authorities and 75% of those on antiretroviral treatment
in Switzerland.22 As of January 2018, the SHCS has
a cumulative total of 20,089 patients. Demographic informa-
tion, mode of HIV acquisition, information of risk behavior,
treatment, and other data are collected at 6-month intervals
following the standard protocol.
Ethics Statement
The SHCS was approved by the participating institu-
tions’ ethics committees (Kantonale Ethikkommission Bern,
Ethikkommission des Kantons St. Gallen, Comité Départe-
mental d’Éthique des Spécialités Médicales et de Médecine
Communautaire et de Premier Recours, Kantonale Ethikkom-
mission Zurich, Repubblica e Cantone Ticino–Comitato
Ethico Cantonale, Commission Cantonale d’Éthique de la
Recherche sur l’Être Humain, Ethikkommission beider Basel;
all approvals are available at http://www.shcs.ch/206-%
0Dethic-committee-approval-and-informed-consent). Written
informed consent was obtained from all participants.22
Phylogenetic Tree
Viral pol gene sequences were obtained from patients’
blood as part of HIV-1 routine resistance testing and through
systematic retrospective sequencing of stored plasma sam-
ples. The sequences consisted of the partial pol region,
specifically all of protease and a minimum of reverse
transcriptase codons 28–225. The earliest sequence of
adequate length of each patient (n = 11,922) was used to
construct a maximum-likelihood phylogenetic tree along with
11,390 Los Alamos HIV database background sequences,
obtained by blasting the SHCS sequences against the database
to help identify which clusters likely involved transmission
within Switzerland.23 The phylogenetic tree was constructed
using MUSCLE for sequence alignment against the HIV
reference sequence HXB2. Insertions related to HXB2 and
common resistance mutation positions were removed by the
program TrimAL.24–26 FastTree, which infers a maximum-
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likelihood phylogeny, was used for the final phylogeny
reconstruction.27,28
HLA Data
HLA allelic information was obtained from the SNP
genotype data, using SNP2HLA with the type 1 Diabetes
Genetics Consortium reference panel for HLA imputation
techniques from the exome/SNP data.29–31 The data used in
the analyses were limited to those of HLA class I molecules
(HLA-A, -B, and -C) because of the literature supporting the
key role of HLA class I peptides in HIV control.32,33 The
homogeneity analyses were performed for each HLA gene
and for each classification level. The HLA allelic information
is classified in our data at 3 different levels: 4-digit, 2-digit,
and supertype. The 4-digit classification refers to a specific
peptide sequence of the HLA peptide, whereas 2-digit groups
to serologically similar peptides, or an “allele group.” For
HLA-B, a broader classification scheme by supertype was
also used, following main peptide anchor specificity.34
Pairs Analysis
For the pairs analysis of HLA homogeneity, pairs were
identified as follows: (1) 2 individuals with sequences being
adjacent tips in the phylogeny (“cherries”), (2) having
a maximum cophenetic distance between the 2 individuals’
sequences of 0.03, (3) both being SHCS patients, (4) both
having data on at least a single HLA allele, and (5) not having
any perinatally infected individual.
For each pair analysis (for HLA-A, -B, and -C at 2
levels of allelic specificity in addition to supertype for HLA-
B), the SHCS pairs were scrambled 10,000 times to obtain
a distribution of the average proportion of pairs with a match
on at least a single HLA allele. The proportion of pairs with
an allelic match in the actual SHCS pairs was compared with
the distribution from the randomizations to obtain a P value,
which was used to evaluate whether there is significantly
greater homogeneity in the SHCS pairs compared with if the
same individuals were randomly assorted into the same
number of pairs (see Figure 1, Supplemental Digital Content,
http://links.lww.com/QAI/B328). HLA-B subanalyses were
performed with pairs being stratified by risk groups: men-
who-have-sex-with-men (MSM), heterosexuals (HET), and
intravenous drug users (IDUs). All the above analyses were
then repeated while restricting for individuals of white
ethnicity. To correct for overtesting, the
Benjamini–Hochberg procedure was performed for the pair/
clusters analyses, with a false discovery rate set at 0.05 and
the number of tests equal to 64, the total number of pair/
cluster analyses performed.
Clusters Analysis
For the clusters analyses of HLA homogeneity, clusters
were identified from the phylogeny as follows: (1) forming
a clade of at least 2 individuals’ sequences (thus including
pairs as well), (2) having a maximum cophenetic distance
between any of the individuals’ sequences of 0.03, (3)
comprising individuals who are over 80% from the SHCS,
and (4) having data on at least a single HLA allele for
a minimum of a third of the cluster individuals (0.333 is the
median proportion of HLA coverage in the clusters),
disregarding perinatally infected patients. An individual can
only belong to a single cluster (ie, smaller-nested clusters
are disregarded).
For each clusters analysis (for HLA-A, -B, and -C), the
proportion of all possible individual-to-individual compar-
isons that had an allelic match was calculated (see Figure 2,
Supplemental Digital Content, http://links.lww.com/QAI/
B328). The average intracluster proportion of allelic matching
in the SHCS clusters was compared with a distribution of the
average of 10,000 randomizations where the individuals were
assorted randomly into the same number of clusters of the
same sizes. This yielded a P value determining whether there
is significantly greater HLA homogeneity in the SHCS
clusters compared with randomly assorted clusters. An
HLA-B subanalysis was performed with clusters being
stratified by the risk group as in the pairs analysis (at least
two-thirds of a cluster’s individuals must belong to the risk
group to be included).
Protective Allele Analysis
To better understand the nature of the HLA alleles
found in the transmission phylogeny, the distribution of 2
HLA-B alleles, B27 and B57, both protective in terms of
HIV-disease progression, was examined for patients within
the transmission pairs and clusters for the HLA-B 2-digit
analysis and those outside of any pair/cluster.35 We used a Z
test for 2 proportions to test whether the protective alleles are
over- or underrepresented in the pairs and clusters.
RESULTS
Demographic Overview
The SHCS consists of 20,089 patients at the time of the
analysis (January 2018), of which about half (n = 11,922) had
at least 1 sequence that was used to construct the transmission
phylogeny (Table 1). Considering the limited coverage of
HLA data on the patients, 336 transmission pairs (phyloge-
netic cherries) were identified as having HLA allelic data for
both individuals and fitting other criteria as explained in the
Methods section, as well as 1319 individuals identified in
valid clusters (see Figure 3, Supplemental Digital Content,
http://links.lww.com/QAI/B328). The individuals in pairs/
clusters are more likely men (78.42% and 81.27% in pairs
and clusters, respectively vs. 72.42% for the whole cohort)
and more likely to be MSM (49.70% and 50.42% vs. 38.65%)
and less likely to be individuals who contracted HIV through
heterosexual contact or intravenous drug usage (Table 1).
This can be explained by the dominance of IDUs in the first
decade of the Swiss epidemic, before the introduction of
highly active antiretroviral treatment and resistance testing
and sequencing, during which most passed away.20 The
predominance of MSM in the pairs/clusters is expected—
most recent HIV infections in Switzerland occurred among
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MSM.36 The patients in the pairs/clusters are more likely of
white ethnicity than in the general SHCS (95.24% and
96.74% vs. 67.75%). This is due to HLA imputation
techniques being validated for those of white ethnicity; hence,
white patients are more likely to have available HLA data. In
addition, white patients generally had greater follow-up
within the cohort, thus being more likely to having had viral
sequencing performed.37 The predominance of
white–nonwhite couples within heterosexual couples is
another factor in the relative underrepresentation of patients
from the heterosexual risk group having HLA data within the
pairs and clusters.36
HLA Homogeneity Analyses
For the pairs analyses, we found greater-than-random
homogeneity for HLA-B. Three hundred one, 325, and 310
pairs were identified, respectively, for the HLA-A, -B, and -C
analyses. When analyzing all pairs unrestricted by the ethnicity
or risk group, there was only a significant difference in HLA
homogeneity observed with the HLA-B supertype analysis,
where 65.5% of the pairs had an HLA-B allele supertype match
compared with an average of 60.8% in the randomly assorted
pairs (P value = 0.014) (Table 2). When restricting to the 59
pairs where both individuals were infected through heterosex-
ual transmission, there was significantly greater than random
HLA-B concordance at the 4-digit and 2-digit levels (4-digit:
25.4% vs. 15.9%, P value = 0.017; 2-digit: 35.6% vs. 23.1%, P
value = 0.006) than compared with the randomly assorted
pairs, although the 4-digit level analysis significant result is
potentially a result of overtesting as suggested after applying
the Benjamini–Hochberg procedure. As for the 34 pairs where
both individuals were IDUs, the HLA-B 2-digit and supertype
analyses demonstrated more HLA-concordant pairs compared
with the randomized pairs [2-digit: 38.2% vs. 24.9%, P value =
0.018 (a potential significant value due to overtesting); super-
type: 82.4% vs. 67.8%, P value = 0.007]. The results were
largely unchanged when restricting to pairs with only white
individuals (see Table 1, Supplemental Digital Content, http://
links.lww.com/QAI/B328).
A similar result was found for the clusters analyses.
Four hundred sixty-nine, 496, and 475 clusters fitting the
defined criteria were identified for the HLA-A, -B, and -C
analyses, respectively (Table 3). The average cluster size
ranged between 3.911 and 3.981 depending on the HLA type,
with about two-thirds of the cluster individuals having HLA
TABLE 1. General Characteristics of SHCS Patients and Those Analyzed in the Pairs and Clusters
Swiss HIV Cohort
Study (SHCS)
SHCS Patients with Sequences
in the Transmission Phylogeny
SHCS Patients in Transmission
Pairs Fitting Criteria
SHCS Patients in Transmission
Clusters Fitting Criteria
Total number 20,089 11,922 672 1319
Median age (IQR) 32.69 (26.78–41.00) 27.00 (33.04–41.23) 33.60 (28.04–39.68) 33.88 (27.85–41.00)
Male (%) 14,548 (72.42) 8554 (71.75) 527 (78.42) 1072 (81.27)
Risk group
MSM (%) 7764 (38.65) 4738 (39.74) 334 (49.70) 665 (50.42)
Heterosexual (%) 6624 (32.97) 4245 (35.61) 205 (30.51) 340 (25.78)
Intravenous drug
user (%)
4824 (24.01) 2430 (20.38) 116 (17.26) 276 (20.92)
Others (%) 877 (4.37) 509 (4.27) 17 (2.53) 38 (2.88)
White (%) 13,611 (67.75) 9199 (77.16) 640 (95.24) 1276 (96.74)
Overall demographic information of patients in the SHCS, as well as those represented in the transmission phylogeny, and those with HLA data in the analyzed pairs and clusters as
fitting the criteria (described in the Materials and Methods section).
IQR, interquartile range.
TABLE 2. Statistical Analyses of HLA Homogeneity in
Transmission Pairs
HLA-Type
(Risk
Group)
HLA
Analysis
Level
No. of
Pairs
Mean
Proportion
of Pairs
With
a Match
Average
Value in
Randomizations P
A (all) 4-digit 301 0.405 0.380 0.131
2-digit 0.442 0.415 0.120
B (all) 4-digit 325 0.200 0.182 0.168
2-digit 0.265 0.241 0.136
Supertype 0.655 0.608 0.014
C (all) 4-digit 310 0.271 0.287 0.718
2-digit 0.406 0.420 0.691
B (MSM) 4-digit 142 0.190 0.192 0.468
2-digit 0.239 0.249 0.560
Supertype 0.648 0.606 0.087
B (HET) 4-digit 59 0.254 0.159 0.017*
2-digit 0.356 0.231 0.006
Supertype 0.695 0.636 0.093
B (IDU) 4-digit 34 0.265 0.184 0.064
2-digit 0.382 0.249 0.018*
Supertype 0.824 0.678 0.007
Overview of statistical analyses measuring HLA allelic homogeneity in transmission
pairs (proportion of pairs with at least 1 matching HLA allele). Different analyses were
performed analyzing varying HLA types (A, B, and C), levels of HLA classification
specificity (4-digit, 2-digit, and supertype), and risk groups (all individuals, MSM, HET,
and heterosexual). Significant P values of tests (,0.05) are denoted in bold.
*Significant P values that become nonsignificant after the Benjamini–Hochberg
procedure, taking into account 64 total tests, with a false discovery rate of 0.05.
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data (Table 3). HLA-B 2-digit and supertype analyses
demonstrated a higher average proportion of intracluster
comparisons with an allelic match compared with randomized
clusters (2-digit: 0.291 vs. 0.251, P value = 0.009; supertype:
0.659 vs. 0.611, P value = 0.002). A similar pattern was
found when restricted to clusters where at least two-thirds of
the individuals are HETs [4-digit: 0.249 vs. 0.162, P value =
0.010; 2-digit: 0.371 vs. 0.244, P value = 0.002; supertype:
0.714 vs. 0.637, P value = 0.027 (potential significant value
due to over-testing)] and IDUs (2-digit: 0.341 vs. 0.246, P
value = 0.010; supertype: 0.699 vs. 0.602, P value = 0.007).
The results were essentially unchanged in the white ethnicity
subanalysis (see Table 2, Supplemental Digital Content,
http://links.lww.com/QAI/B328).
The 3 levels of analyses across the 3 HLA types are
summarized in Figure 1, showing greater HLA homogeneity
TABLE 3. Statistical Analyses of HLA Homogeneity in Transmission Clusters
HLA-Type
(Risk Group)
HLA
Analysis
Level
No. of
Clusters
Average
Cluster Size
Average Percentage of
Individuals in Clusters with
HLA Data
Mean Proportion of
Intracluster Matches
Average Value in
Randomizations in
Clusters P
A (all) 4-digit 469 3.981 65.82 0.379 0.376 0.447
2-digit 0.413 0.411 0.456
B (all) 4-digit 496 3.911 66.47 0.191 0.185 0.329
2-digit 0.291 0.251 0.009
Supertype 0.659 0.611 0.002
C (all) 4-digit 475 3.979 66.35 0.294 0.293 0.478
2-digit 0.410 0.425 0.810
4-digit 0.171 0.193 0.695
B (MSM) 2-digit 214 4.000 69.51 0.245 0.253 0.616
Supertype 0.642 0.615 0.131
4-digit 0.249 0.162 0.010
B (HET) 2-digit 81 3.037 76.02 0.371 0.244 0.002
Supertype 0.714 0.637 0.027*
4-digit 0.222 0.183 0.137
B (IDU) 2-digit 78 4.641 57.73 0.341 0.246 0.010
Supertype 0.699 0.602 0.007
Overview of statistical analyses measuring HLA allelic homogeneity in transmission clusters (average proportion of all comparisons within clusters where at least 1 match exists).
Different analyses were performed analyzing varying HLA types (A, B, and C), levels of HLA classification specificity (4-digit, 2-digit, and supertype), and risk groups (all individuals,
MSM, HET, and heterosexual). Significant P values of tests (,0.05) are denoted in bold.
*Significant P values that become nonsignificant after the Benjamini–Hochberg procedure, taking into account 64 total tests, with a false discovery rate of 0.05.
FIGURE 1. Overview of pairs and clusters analyses and HLA homogeneity. Visual overview of statistical analyses of HLA allelic
homogeneity (average proportion of pairs with at least 1 matching HLA allele or average proportion of all comparisons within
clusters with at least 1 matching allele). Different analyses were performed of the varying HLA class-I types (A, B, and C) and levels
of HLA classification specificity (4-digit, 2-digit, and supertype).
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in SHCS pairs/clusters compared with the randomized pairs/
clusters when analyzing HLA-A and HLA-B, although
significantly greater homogeneity was only observed with
HLA-B 2-digit clusters, supertype pairs, and supertype
clusters. This pattern was not observed for HLA-C. The
highest homogeneity measures were found in the supertype
analyses, followed by the 2-digit and 4-digit analyses, which
is expected considering the greater number of HLA catego-
rizations as specificity increases.
Protective Allele Analysis
As summarized in Table 4, HLA-B27 was shown to not
be under- or overrepresented within the 1297 individuals of
the HLA-B 2-digit analyses compared with the 3412
individuals outside of the pairs/clusters (proportions: 0.076
vs. 0.080, P value = 0.651). HLA-B57 was somewhat
underrepresented for the individuals within the pairs/clusters
with nonsignificant differences (0.067 vs. 0.084, P value =
0.057). The distribution of both protective alleles overall was
not found to be concentrated within or without the pairs/
clusters (0.141 vs. 0.161, P value = 0.094).
DISCUSSIONS
The HIV transmission pairs and clusters in the SHCS
demonstrate significantly greater HLA-B homogeneity than if
the individuals were randomly assorted. These findings were
further strengthened when we restricted to individuals with
white ethnicity to control for race. This observed effect with
HLA-B is in line with other research that suggests the
dominant role of HLA-B in determining HIV pathogene-
sis.14,38,39 This greater role for HLA-B is likely explained by
the HLA-B locus’ greater observed capacity for recombina-
tion and mutation compared with other loci. Considering
HLA-B’s greater peptide-binding versatility, it is thus no
surprise that the virus’ ability to escape HLA-B binding is
critical to escape.40
Several processes could explain our findings. If the
virus is transmitted within a cluster between individuals with
similar HLA alleles, then the developed escape mutations that
are transmitted do not require further mutations or reversions
to the wild type as the virus is already primed to the
respective HLA context of the newly infected individuals.
Goulder et al41 suggested in their article demonstrating an
association between mother–child HLA concordance and
transmission that cytotoxic T lymphocyte (CTL) escape
pressure could increase viremia and transmissibility. Such
a mechanism would be supported by the literature suggesting
faster disease progression in the recipient where there is an
HLA match between a transmission pair.42 In such a scenario,
larger clusters would demonstrate greater HLA homogeneity.
Another potential mechanism behind the greater homogeneity
may involve superinfection. If an individual was super-
infected by a second strain of HIV, the superinfecting strain
may have a greater probability to supplant the resident strain
if it is preadapted to the HLA alleles of the recipient, which is
more likely if recipient and new transmitter are HLA con-
cordant. In such a scenario, the transmission phylogeny
would show a phylogenetic affinity between 2 HLA-
concordant individuals even if the identified infecting indi-
vidual was not the primary transmitter. Previous research
estimates the annual incidence of HIV superinfection in
already infected individuals to be as high as 7.7%, which
could explain the appearance of people with similar HLA-B
types clustering together in our analysis, particularly among
IDUs who may experience more superinfection events.43,44
This being said, we emphasize that our study and findings are
exploratory in nature. We are thus unable to assert a mecha-
nism, novel or not, behind these observations.
Mate choice and geographic clustering are often
identified as confounders in HLA-related studies. Some
studies have suggested that partner choice in humans may
preferentially occur between HLA-discordant individuals as
to increase offspring HLA diversity.45 However, the evidence
for this is inconclusive.46 Regardless, our interpretation of the
results would be unaffected—any mate selection effect would
mean we would expect the null hypothesis to be dispropor-
tionately greater heterogeneity. Such a scenario would only
strengthen the significance of the observed homogeneity in
our data. In addition, only about a quarter of the SHCS
individuals analyzed in our study are classified as having
heterosexual contact as the transmission route, whereas about
half are MSM (Table 1). No research to date examines how
MSM partner selection may be related to HLA concordance.
Another potential confounder is geographic cluster-
ing, where HLA types tend to appear at different frequen-
cies in different regions due to migration patterns and
selection pressures that geographically vary; thus, people
who live near each other are more likely to be HLA
concordant.47 We believe that such confounding can be
mostly disregarded in our setting for the following reason:
despite the HLA variation within Switzerland, the large
majority of the individuals in our study are MSM or
IDUs.48 These 2 high-risk populations cluster in urban
areas, forming subpopulations with people from diverse
regions, largely eliminating geographic confounding for
our study context.49,50 If geography or mate selection were
to play a role in our observed results, then we would have
observed HLA-A and -C homogeneity as well, which we
do not.
TABLE 4. Distribution of Protective HLA Alleles B27 and B57
Within and Without the HLA-B Pairs/Clusters Analyses
HLA
Allele
Proportion Having
Protective Allele
within Pairs/Clusters
Analyzed (n = 1297)
Proportion Having
Protective Allele
outside Pairs/Clusters
Analyzed (n = 3412)
P of Z-test of
2 Proportions
B27 0.076 (99) 0.080 (274) 0.651
B57 0.067 (87) 0.084 (286) 0.057
B27
or
B57
0.141 (183) 0.161 (549) 0.094
Distribution of protective HLA-B alleles 27 and 57 inside and outside the pairs and
clusters analyzed for the HLA-B 2-digit analyses, and the Z-test P values indicating if
protective alleles are significantly over- or underrepresented in patients in the
pairs/clusters.
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In the subanalyses of IDUs, the subpopulation initially
hardest hit by the Swiss HIV epidemic, we found even more
significant HLA-B homogeneity at the 2-digit and supertype
levels of analysis compared with the main analyses. Frequent
needle sharing combined with the higher chance of HIV
transmission by intravenous needle usage compared with
sexual transmission routes (except receptive anal intercourse)
may lead to more superinfection events among IDUs, leading
to greater observed HLA homogeneity.51
Another potential explanation for the greater effect
among IDUs may be that the IDUs in the Swiss cohort were
primarily infected in the early phases of the epidemic. As
research suggests greater CTL escape mutations with the
progression of the epidemic, it is possible that the pattern
described in our study attenuates with the passage of time and
is thus more pronounced among IDUs.16,19
Because roughly half of HIV+ people in Switzerland
are in the SHCS, the transmission clusters are missing
individuals that would otherwise be included, meaning that
some transmission pairs are not true pairs but are instead part
of a transmission network with the intermediary individuals
missing. Furthermore, only a fraction of the individuals in the
SHCS had HLA data, which could be used in our analysis.
However, such an effect would just dilute our findings, as
opposed to artificially increasing observed homogeneity.52
This combined with the high coverage of the SHCS compared
with other HIV cohort studies strengthens our confidence in
our findings.
The novel population-level approach used in this article
provides new insights into HIV and HLA’s coevolutionary
dynamics, posing new questions about the mechanisms that HIV
uses to adapt to the host’s HLA type. Our study provides the first
indication that HLA diversity is a selective factor for HIV-1 at
the population level and not just at the individual level.
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